Skip to main content

Table 3 Target mRNA levels in 2 NSCLC xenografts after bevacizumab treatment

From: Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings

  NSCLC#3 NSCLC#5
   Control (n=5) After bevacizumab reatment (n=5) p-value 1 Control (n=5) After bevacizumab treatment (n=5) p-value 1
PECAM1/CD31 mRNA Human 18.1 (7.34-43.1) 57.6 (31.8-64.2) <0.05 2.38 (0.00-9.21) 6.70 (2.41-17.1) NS  
  Mouse 863 (686-1790) 578 (483-847) <0.05 2 334 (1 538-4 363) 856 (699-980) <0.05
ENG/CD105 mRNA Human 29.1 (3.59-47.2) 38.2 (15.1-71.4) NS 57.64 (38.8-90.86) 57.50 (47.2 - 84.4) NS
  Mouse 619 (580-1098) 414 (328-619) <0.05 1 519 (1120-1813) 821 (610-860) <0.05
FLT1/VEGFR1 mRNA Human 59.6 (56.7-90.6) 88.9 (62.3-118) NS 3.84 (0.00-24.8) 9.11 (3.87-20.3) NS
  Mouse 589 (470-909) 274 (212-362) <0.05 938 (633-1163) 305 (216-344) <0.05
KDR/VEGFR2 mRNA Human 507 (361-622) 545 (488-643) NS 220 (140-274) 574 (213-834) NS
  Mouse 466 (386-800) 204 (196-298) <0.05 1 175 (698-1 211) 328 (316-349) <0.05
VEGFA mRNA Human 20 503 (19162-24600) 32 160 (30 331-35 680) <0.05 11 984 (5 368-13 961) 12 235 (7 088-14 042) NS
  Mouse 160 (119-495) 307 (184-614) NS 262 (170-680) 267 (240-360) NS
  1. Results are expressed as normalized N-fold differences in target gene expression relative to the ‘Total-TBP’ expression. These Ntarget values of the tumor samples were normalized such that the value for the ’basal mRNA level‘ (Ct = 35) was 1Target mRNA levels that were total absence or very low (Ct > 38) in tumor samples were scored ‘0’ for non expressed.
  2. Median and range in () are given for each gene in the different experimental conditions. 1Mann Whitney Test; NS, not significant; in bold, significant.